1. Show article details.

    Amgen, Adaptive Biotechnologies ink COVID-19 antibody development collaboration

    MarketWatch – 9:34 AM ET 04/02/2020

    Shares of Amgen Inc. (AMGN) gained 1.2% in trading on Thursday after the drugmaker announced that it is collaborating with Adaptive Biotechnologies Corp. (ADPT) to discover and develop antibodies that can be used to prevent or treat COVID-19. Adaptive's stock was down 0.9%. Financial terms of the exclusive collaboration will be finalized "in the coming weeks," the companies said.

  2. Show article details.

    BRIEF-Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

    Reuters – 9:05 AM ET 04/02/2020

    Adaptive Biotechnologies Corp (ADPT): * AMGEN AND ADAPTIVE BIOTECHNOLOGIES ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP A THERAPEUTIC TO PREVENT OR TREAT COVID-19. * Adaptive Biotechnologies Corp (ADPT) - COMPANIES WILL BEGIN WORK IMMEDIATELY. * Adaptive Biotechnologies Corp (ADPT) - TERMS OF AGREEMENT ARE NOT BEING DISCLOSED.

  3. Show article details.

    Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

    PR Newswire – 9:00 AM ET 04/02/2020

    THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020  Amgen (AMGN) and Adaptive Biotechnologies (ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus.

  4. Show article details.

    BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan

    Reuters – 8:18 PM ET 03/31/2020

    Amgen Inc (AMGN): * AMGEN ESTABLISHES WHOLLY-OWNED AFFILIATE IN JAPAN. * CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS Source text for Eikon: Further company coverage:

  5. Show article details.

    Amgen Establishes Wholly-Owned Affiliate In Japan

    PR Newswire – 8:00 PM ET 03/31/2020

    THOUSAND OAKS, Calif. "With roughly one-quarter of its population 65 or older, Japan will require ever more innovative medicines to treat diseases associated with the aging process," said Robert A. Bradway, chairman and chief executive officer of Amgen.

  6. Show article details.

    BRIEF-Amgen - Have Temporarily Paused Enrollment/Screening In Clinical Trials Where There Is Uncertainty Around Ability Of Sites To Ensure Subject Safety

    Reuters – 8:49 AM ET 03/31/2020

    Amgen Inc (AMGN): * AMGEN (AMGN) - HAVE TEMPORARILY PAUSED ENROLLMENT/SCREENING IN CLINICAL TRIALS WHERE THERE IS UNCERTAINTY AROUND ABILITY OF SITES TO ENSURE SUBJECT SAFETY. * Amgen Inc (AMGN) - MADE DECISION TO SUSPEND ALL IN-PERSON MEETINGS AND INTERACTIONS WITH HEALTHCARE COMMUNITY AND PROFESSIONALS IN U.S. * Amgen Inc (AMGN) - AT THIS STAGE OF COVID-19 PANDEMIC, CANNOT RULE OUT FUTURE IMPACT ON CO'S BUSINESS.

  7. Amgen upgraded to outperform from market perform at Raymond James

    MarketWatch – 7:17 AM ET 03/30/2020
  8. Show article details.

    BRIEF-Amgen Says Positive Results From Phase 3B Study Of Repatha In People With HIV Who Have High Ldl-Cholesterol

    Reuters – 1:15 PM ET 03/28/2020

    Amgen Inc (AMGN): * Amgen Inc (AMGN) -POSITIVE RESULTS AT ACC.20/WCC FROM PHASE 3B STUDY OF REPATHA® IN PEOPLE LIVING WITH HIV WHO HAVE HIGH LDL-CHOLESTEROL. * AMGEN INC SAYS STUDY MET PRIMARY ENDPOINT AND ALL SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:

  9. Show article details.

    Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol

    PR Newswire – 10:00 AM ET 03/28/2020

    THOUSAND OAKS, Calif. "Certain antiretroviral treatments for HIV can increase LDL-C and change the lipid makeup of people living with HIV.

  10. Show article details.

    Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts

    PR Newswire – 4:01 PM ET 03/23/2020

    THOUSAND OAKS, Calif. "The COVID-19 pandemic is precipitating a series of unprecedented challenges for people, governments and healthcare systems around the globe. Free online learning programs supported by the Amgen Foundation are also available to help students continue their science education during school closures, including LabXchange™ and Khan Academy's online learning website.

  11. Show article details.

    BRIEF-Amgen Announces 2020 Second Quarter Dividend

    Reuters – 4:31 PM ET 03/04/2020

    Amgen Inc (AMGN): * AMGEN ANNOUNCES 2020 SECOND QUARTER DIVIDEND. * SETS QUARTERLY DIVIDEND OF $1.60PER SHARE Source text for Eikon: Further company coverage:

  12. Show article details.

    Amgen Announces 2020 Second Quarter Dividend

    PR Newswire – 4:04 PM ET 03/04/2020

    THOUSAND OAKS, Calif. About AmgenAmgen (AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen (AMGN) focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  13. Show article details.

    Amgen To Present At The Cowen 40th Annual Healthcare Conference

    PR Newswire – 8:00 PM ET 02/27/2020

    THOUSAND OAKS, Calif. About Amgen Amgen (AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen (AMGN) focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  14. Show article details.

    Biohaven drug wins U.S. FDA approval for use in relieving migraine headaches

    Reuters – 6:11 PM ET 02/27/2020

    The U.S. Food and Drug Administration on Thursday approved Biohaven Pharmaceutical Holding Co Ltd's (BHVN) oral pill for relieving pain after the onset of migraine headaches, the drug developer said. The company's shares were up 5.3% at $40.82 in extended trading.

  15. Show article details.

    BRIEF-Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

    Reuters – 8:41 AM ET 02/26/2020

    Cytokinetics Inc (CYTK): * AMGEN (AMGN), CYTOKINETICS AND SERVIER ANNOUNCE CONTINUATION OF GALACTIC-HF FOLLOWING PLANNED INTERIM ANALYSIS. * CYTOKINETICS-DATA MONITORING COMMITTEE RECOMMENDS PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH HEART FAILURE CONTINUE WITHOUT CHANGES. * Cytokinetics Inc (CYTK) - TOPLINE RESULTS EXPECTED IN Q4 2020 Source text for Eikon: Further company coverage:

  16. Show article details.

    Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

    PR Newswire – 8:30 AM ET 02/26/2020

    THOUSAND OAKS, Calif. The second interim analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial's protocol.

  17. Show article details.

    Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

    GlobeNewswire – 8:30 AM ET 02/26/2020

    Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes Topline Results Expected in Q4 2020 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee for GALACTIC-HF recently complete...

  18. Show article details.

    Drug pricing review group signs deal with Aetion for patient data

    Reuters – 8:00 AM ET 02/24/2020

    The Institute for Clinical and Economic Review, a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly.

  19. Show article details.

    U.S. FDA approves Lundbeck's migraine prevention therapy

    Reuters – 7:37 PM ET 02/21/2020

    The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.

  20. Show article details.

    BRIEF-Amgen Inc Says On Feb 21, Issued And Sold $500 Million Of 1.900% Senior Notes Due 2025, $750 Million Of 2.200% Senior Notes Due 2027

    Reuters – 6:23 PM ET 02/21/2020

    Amgen Inc (AMGN): * Amgen Inc (AMGN) - ON FEB 21, ISSUED AND SOLD $500 MILLION OF 1.900% SENIOR NOTES DUE 2025, $750 MILLION OF 2.200% SENIOR NOTES DUE 2027. * Amgen Inc (AMGN) - 2025 NOTES WILL MATURE ON FEB 21, 2025, 2027 NOTES WILL MATURE ON FEB 21, 2027. * Amgen Inc (AMGN) - 2030 NOTES WILL MATURE ON FEB 21, 2030, 2040 NOTES WILL MATURE ON FEB 21, 2040 AND 2050 NOTES WILL MATURE ON FEB 21, 2050.

Page:

Today's and Upcoming Events

  • May
    15

    AMGN ex-Dividend for $1.60 on 05/15/2020

    • Announce Date: 03/04/2020
    • Record Date: 05/18/2020
    • Pay Date: 06/08/2020
  • Apr
    30

    AMGN to announce Q1 earnings (Confirmed)

Past Events (last 90 days)

  • Feb
    13

    AMGN ex-Dividend for $1.60 on 02/13/2020

    • Announce Date: 12/11/2019
    • Record Date: 02/14/2020
    • Pay Date: 03/06/2020
  • Jan
    30

    AMGN announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.